| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 30 | 2024 | 127 | 6.240 |
Why?
|
| Cadherins | 14 | 2024 | 174 | 5.290 |
Why?
|
| Lupus Erythematosus, Systemic | 9 | 2025 | 225 | 2.860 |
Why?
|
| Arthritis, Rheumatoid | 15 | 2026 | 285 | 2.770 |
Why?
|
| Antirheumatic Agents | 8 | 2026 | 118 | 2.280 |
Why?
|
| Macrophages | 5 | 2024 | 643 | 1.780 |
Why?
|
| Skin | 7 | 2024 | 517 | 1.530 |
Why?
|
| Autoantibodies | 11 | 2019 | 423 | 1.370 |
Why?
|
| Skin Diseases | 3 | 2018 | 137 | 1.140 |
Why?
|
| Autoimmune Diseases | 7 | 2024 | 270 | 1.130 |
Why?
|
| Pulmonary Fibrosis | 4 | 2022 | 111 | 1.130 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 447 | 1.120 |
Why?
|
| Fibroblasts | 11 | 2024 | 820 | 1.120 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 3271 | 1.110 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 4448 | 1.060 |
Why?
|
| Rheumatic Diseases | 5 | 2024 | 74 | 1.010 |
Why?
|
| Fibrosis | 9 | 2024 | 400 | 1.010 |
Why?
|
| Synovitis | 2 | 2020 | 24 | 0.910 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 217 | 0.900 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2024 | 174 | 0.880 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 253 | 0.870 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 112 | 0.850 |
Why?
|
| Dendritic Cells | 3 | 2024 | 435 | 0.830 |
Why?
|
| Liver | 2 | 2022 | 1765 | 0.790 |
Why?
|
| Phagocytosis | 2 | 2024 | 191 | 0.790 |
Why?
|
| Machine Learning | 1 | 2026 | 325 | 0.750 |
Why?
|
| Medication Adherence | 1 | 2026 | 330 | 0.750 |
Why?
|
| Extracellular Matrix | 4 | 2019 | 223 | 0.740 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 15 | 0.740 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 1732 | 0.700 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 386 | 0.690 |
Why?
|
| Patient Compliance | 1 | 2024 | 464 | 0.680 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 483 | 0.660 |
Why?
|
| Uveitis | 1 | 2020 | 33 | 0.660 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 398 | 0.660 |
Why?
|
| Sarcoidosis | 1 | 2020 | 50 | 0.650 |
Why?
|
| Vaccination | 1 | 2025 | 1004 | 0.640 |
Why?
|
| Arthritis | 1 | 2020 | 84 | 0.640 |
Why?
|
| Myofibroblasts | 3 | 2019 | 60 | 0.630 |
Why?
|
| Monocytes | 1 | 2022 | 330 | 0.630 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 74 | 0.620 |
Why?
|
| Rheumatology | 4 | 2024 | 129 | 0.620 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2019 | 2 | 0.610 |
Why?
|
| Bleomycin | 7 | 2024 | 110 | 0.600 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2015 | 134 | 0.590 |
Why?
|
| Naphthols | 1 | 2018 | 8 | 0.590 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2017 | 2754 | 0.580 |
Why?
|
| Medical History Taking | 1 | 2019 | 108 | 0.580 |
Why?
|
| Humans | 72 | 2026 | 127514 | 0.570 |
Why?
|
| Watchful Waiting | 1 | 2019 | 73 | 0.570 |
Why?
|
| Sulfonamides | 2 | 2024 | 280 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 989 | 0.540 |
Why?
|
| Immunologic Factors | 2 | 2011 | 182 | 0.540 |
Why?
|
| Mice | 20 | 2024 | 17695 | 0.530 |
Why?
|
| Animals | 26 | 2024 | 33213 | 0.520 |
Why?
|
| Autoimmunity | 2 | 2024 | 172 | 0.510 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2016 | 13 | 0.490 |
Why?
|
| Strongyloides stercoralis | 1 | 2016 | 24 | 0.490 |
Why?
|
| Strongyloidiasis | 1 | 2016 | 50 | 0.480 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 137 | 0.460 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1871 | 0.450 |
Why?
|
| Mice, Knockout | 8 | 2024 | 3720 | 0.450 |
Why?
|
| Inflammation | 3 | 2024 | 1435 | 0.430 |
Why?
|
| Female | 35 | 2026 | 68771 | 0.400 |
Why?
|
| Cell Adhesion | 4 | 2022 | 299 | 0.390 |
Why?
|
| Hypertension, Pulmonary | 3 | 2023 | 453 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 4513 | 0.380 |
Why?
|
| Hemorrhage | 1 | 2016 | 492 | 0.380 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 875 | 0.370 |
Why?
|
| Rheumatoid Factor | 1 | 2011 | 6 | 0.360 |
Why?
|
| HLA Antigens | 4 | 2024 | 217 | 0.360 |
Why?
|
| Osteopontin | 1 | 2012 | 51 | 0.360 |
Why?
|
| Cytokines | 6 | 2019 | 1326 | 0.360 |
Why?
|
| Managed Care Programs | 1 | 2011 | 56 | 0.360 |
Why?
|
| CD58 Antigens | 1 | 2011 | 7 | 0.350 |
Why?
|
| Male | 36 | 2026 | 62896 | 0.350 |
Why?
|
| Epithelial Cells | 1 | 2015 | 873 | 0.340 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2011 | 19 | 0.340 |
Why?
|
| CD11b Antigen | 1 | 2011 | 35 | 0.340 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3714 | 0.340 |
Why?
|
| Genetic Loci | 2 | 2011 | 342 | 0.320 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 238 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 2999 | 0.320 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2901 | 0.320 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 22 | 0.320 |
Why?
|
| Middle Aged | 19 | 2025 | 27894 | 0.320 |
Why?
|
| OX40 Ligand | 1 | 2009 | 9 | 0.310 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 37 | 0.310 |
Why?
|
| Interferon-alpha | 1 | 2011 | 237 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 888 | 0.290 |
Why?
|
| Lung | 2 | 2015 | 1524 | 0.290 |
Why?
|
| Synovial Fluid | 1 | 2008 | 17 | 0.280 |
Why?
|
| Withholding Treatment | 1 | 2008 | 71 | 0.280 |
Why?
|
| Cell Communication | 2 | 2008 | 190 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2011 | 553 | 0.270 |
Why?
|
| Glucocorticoids | 3 | 2024 | 337 | 0.270 |
Why?
|
| Myositis | 2 | 2024 | 100 | 0.270 |
Why?
|
| United States | 9 | 2026 | 11428 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 638 | 0.250 |
Why?
|
| Adult | 17 | 2025 | 30609 | 0.250 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2019 | 9 | 0.250 |
Why?
|
| Antigens, CD | 1 | 2008 | 415 | 0.240 |
Why?
|
| Hospitals, University | 1 | 2005 | 103 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 217 | 0.230 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2024 | 11 | 0.210 |
Why?
|
| Phagocytes | 1 | 2024 | 24 | 0.210 |
Why?
|
| Terpenes | 1 | 2024 | 30 | 0.210 |
Why?
|
| Lipoblastoma | 1 | 2023 | 6 | 0.200 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 516 | 0.200 |
Why?
|
| Myeloid Cells | 1 | 2024 | 106 | 0.200 |
Why?
|
| Young Adult | 4 | 2025 | 9705 | 0.200 |
Why?
|
| Liposomes | 1 | 2024 | 196 | 0.200 |
Why?
|
| Macrophages, Alveolar | 2 | 2014 | 48 | 0.200 |
Why?
|
| Genotype | 6 | 2011 | 2600 | 0.200 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 29 | 0.190 |
Why?
|
| Psoriasis | 1 | 2023 | 52 | 0.190 |
Why?
|
| Medicare | 1 | 2026 | 424 | 0.190 |
Why?
|
| Collagen | 3 | 2019 | 292 | 0.190 |
Why?
|
| Antigens, Ly | 1 | 2022 | 32 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 128 | 0.180 |
Why?
|
| Antibodies, Antinuclear | 2 | 2011 | 31 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Biological Products | 1 | 2023 | 138 | 0.170 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.170 |
Why?
|
| Polymorphism, Genetic | 1 | 2024 | 788 | 0.170 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2020 | 11 | 0.170 |
Why?
|
| Vitamin D | 2 | 2019 | 181 | 0.160 |
Why?
|
| Signal Transduction | 6 | 2019 | 4489 | 0.160 |
Why?
|
| Encephalitis | 1 | 2021 | 117 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 75 | 0.160 |
Why?
|
| Carbon Tetrachloride | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2017 | 4988 | 0.150 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 28 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 458 | 0.150 |
Why?
|
| Iron, Dietary | 1 | 2019 | 14 | 0.150 |
Why?
|
| Disease Progression | 4 | 2024 | 2125 | 0.150 |
Why?
|
| Case-Control Studies | 7 | 2023 | 3332 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 200 | 0.150 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2018 | 3 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 110 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 757 | 0.140 |
Why?
|
| Muromegalovirus | 1 | 2017 | 12 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 431 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2019 | 231 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2020 | 267 | 0.130 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
|
| Apoptosis | 1 | 2024 | 1823 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 78 | 0.130 |
Why?
|
| Ustekinumab | 1 | 2017 | 3 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 111 | 0.130 |
Why?
|
| Arthralgia | 1 | 2017 | 72 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 150 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2026 | 17081 | 0.130 |
Why?
|
| Aged | 7 | 2026 | 20519 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 258 | 0.130 |
Why?
|
| Synovial Membrane | 2 | 2007 | 26 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 333 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2026 | 6718 | 0.130 |
Why?
|
| Herpesviridae Infections | 1 | 2017 | 139 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 342 | 0.120 |
Why?
|
| Dermis | 2 | 2016 | 23 | 0.120 |
Why?
|
| Up-Regulation | 3 | 2019 | 827 | 0.120 |
Why?
|
| Methotrexate | 3 | 2023 | 317 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 97 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2011 | 81 | 0.110 |
Why?
|
| Biomarkers | 5 | 2022 | 3253 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2010 | 1774 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 41 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1395 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4804 | 0.110 |
Why?
|
| Biopsy | 1 | 2017 | 1237 | 0.100 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 23 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 1008 | 0.100 |
Why?
|
| Child | 3 | 2024 | 25298 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 96 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 177 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2017 | 339 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 406 | 0.100 |
Why?
|
| Transcriptome | 1 | 2019 | 1072 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 44 | 0.090 |
Why?
|
| Smad2 Protein | 1 | 2012 | 52 | 0.090 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 13 | 0.090 |
Why?
|
| Genetic Markers | 2 | 2011 | 599 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 105 | 0.090 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 123 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 22 | 0.090 |
Why?
|
| France | 1 | 2011 | 86 | 0.090 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 6 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 20156 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 14 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2038 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 852 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12582 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 10 | 0.080 |
Why?
|
| Interleukin-23 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 221 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 91 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 1148 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 766 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 137 | 0.080 |
Why?
|
| Centromere | 1 | 2009 | 67 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 205 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 94 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2010 | 808 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 90 | 0.080 |
Why?
|
| Neoplasms | 2 | 2023 | 2857 | 0.070 |
Why?
|
| Interferons | 1 | 2010 | 136 | 0.070 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 110 | 0.070 |
Why?
|
| Leukocytes | 2 | 2010 | 204 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2009 | 124 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 524 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 314 | 0.070 |
Why?
|
| Alleles | 2 | 2011 | 1610 | 0.070 |
Why?
|
| Mass Screening | 2 | 2024 | 805 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 116 | 0.070 |
Why?
|
| Social Support | 1 | 2011 | 369 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2240 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 662 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 787 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 421 | 0.070 |
Why?
|
| Risk Factors | 4 | 2011 | 10636 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1601 | 0.070 |
Why?
|
| Family | 1 | 2010 | 580 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1110 | 0.060 |
Why?
|
| Mutation | 1 | 2020 | 5950 | 0.060 |
Why?
|
| Cell Line | 1 | 2011 | 2566 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1602 | 0.060 |
Why?
|
| Adherens Junctions | 1 | 2006 | 15 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 382 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2048 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 542 | 0.060 |
Why?
|
| Massachusetts | 1 | 2005 | 116 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 65 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2005 | 77 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2587 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 79 | 0.060 |
Why?
|
| rho-Associated Kinases | 2 | 2016 | 47 | 0.060 |
Why?
|
| Lipids | 1 | 2008 | 551 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3588 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 6250 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1277 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 163 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2011 | 740 | 0.050 |
Why?
|
| Peptides | 1 | 2008 | 830 | 0.050 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2024 | 4 | 0.050 |
Why?
|
| Phenotype | 2 | 2011 | 4309 | 0.050 |
Why?
|
| Walk Test | 1 | 2024 | 30 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2024 | 17 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 409 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 735 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 650 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 220 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 168 | 0.050 |
Why?
|
| Mesentery | 1 | 2023 | 27 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2024 | 284 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2024 | 97 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 98 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2022 | 75 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 227 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 26 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2003 | 108 | 0.050 |
Why?
|
| Tretinoin | 1 | 2022 | 93 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2008 | 538 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1601 | 0.050 |
Why?
|
| Recurrence | 1 | 2005 | 1422 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 204 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2022 | 160 | 0.040 |
Why?
|
| RNA Interference | 1 | 2023 | 494 | 0.040 |
Why?
|
| Actins | 2 | 2017 | 311 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 631 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2020 | 16 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2020 | 19 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 496 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 344 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 363 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 349 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 429 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 127 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 444 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2019 | 52 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 506 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 654 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 46 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2017 | 42 | 0.030 |
Why?
|
| Mastectomy | 1 | 2017 | 74 | 0.030 |
Why?
|
| Androstadienes | 1 | 2017 | 50 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2019 | 287 | 0.030 |
Why?
|
| Virus Activation | 1 | 2017 | 84 | 0.030 |
Why?
|
| Interleukin-15 | 1 | 2017 | 100 | 0.030 |
Why?
|
| Glycolysis | 1 | 2017 | 169 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 87 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 623 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 315 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 25 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 32 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 384 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 258 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 46 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 417 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 398 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 219 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 528 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 257 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 680 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 373 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 99 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 67 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 16 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1371 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2014 | 151 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 134 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 1081 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 46 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1438 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2013 | 48 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 578 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2016 | 676 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 247 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 226 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1019 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2017 | 776 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 275 | 0.020 |
Why?
|
| Immunogenetics | 1 | 2011 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3720 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 45 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1374 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2400 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 611 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2010 | 2 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 315 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 12 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1206 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 60 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 32 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1487 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 103 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 78 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 186 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 154 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 73 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 37 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2542 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12810 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 525 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1501 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 438 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 14463 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1563 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 20 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2111 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1218 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 144 | 0.020 |
Why?
|
| Vinculin | 1 | 2006 | 6 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1092 | 0.020 |
Why?
|
| Reticulin | 1 | 2006 | 7 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 64 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 450 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1540 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 948 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2010 | 1509 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 167 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5160 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 954 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1712 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1338 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 3565 | 0.010 |
Why?
|